Offer Request Form

Order list is empty

Shikari® (S-ATR) Anti-Rituximab ELISA

Enzyme immunoassay for the qualitative determination of specific antibodies to of Rituximab (Rituxan®, Mabthera®) in serum and plasma.

This kit has been especially developed for the qualitative determination of specific antibodies to Rituximab in serum and plasma samples.

The Matriks Biotek Antibody to Rituximab (Rituxan®, Mabthera®) Enzyme-Linked-Immuno-Sorbent-Assay (ELISA) Kit is intended for the qualitative determination of antibodies to rituximab (Rituxan®, Mabthera®) in serum and plasma.Measurement of biological drug trough levels and antibody to biological drug gained high importance during the course of treatment. These measurements enable dose adjustments and switch to another class of biological drug when necessary.

All SHIKARI® ELISA kits are suitable for biosimilar work.

All SHIKARI® ELISA kits are produced under ISO 13485 quality system and have CE IVD mark.

For technical inquiry, please contact


Required Volume (µl) 20
Total Time (min) 140
Sample Serum, plasma
Sample Number 96
Detection Limit (ng/mL) + / -
Spike Recovery (%) -
Shelf Life (year) 1
Assay type Qualitative
Species Reactivity Human
Storage conditions Store at +4°C. Please refer to protocols.
Shipping conditions At room temperature
# File Action
Instructions For Use Download
Safety Data Sheet (SDS) Download

Publications with this drug

# File Action
Sinha, Aditi, et al. "Sequential rituximab therapy sustains remission of nephrotic syndrome, but carries high risk of adverse effects." Nephrology Dialysis Transplantation (2022). Visit Link
Chen, Yewei, et al. "Population Pharmacokinetics of Rituximab in Pediatric Patients With Frequent-Relapsing or Steroid-Dependent Nephrotic Syndrome." Frontiers in Pharmacology (2021): 2348. Visit Link
Liu, Shu, et al. "Rituximab exposure‐response in triweekly R‐CHOP treatment in DLBCL: A loading dose is recommended to improve clinical outcomes." Clinical and Translational Science (2021). Visit Link
Liu, Shu, et al. "Low initial trough concentration of rituximab is associated with unsatisfactory response of first-line R-CHOP treatment in patients with follicular lymphoma with grade 1/2." Acta Pharmacologica Sinica (2020): 1-7. Visit Link
Bai Y, Li W, Yan C, Hou Y, Wang Q. Anti-rituximab antibodies in patients with refractory autoimmune nodopathy with anti-neurofascin-155 antibody. Front Immunol. 2023 Mar 28;14:1121705. Visit Link
Yewei Chen, et al., Using real-world data to inform dosing strategies of rituximab for pediatric patients with frequent-relapsing or steroid-dependent nephrotic syndrome: a prospective pharmacokinetic-pharmacodynamic study Visit Link